These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38185870)

  • 1. A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease.
    Tokita J; Lam D; Vega A; Wang S; Amoruso L; Muller T; Naik N; Rathi S; Martin S; Zabetian A; Liu C; Sinfield C; McNicholas T; Fleming F; Coca SG; Nadkarni GN; Tun R; Kattan M; Donovan MJ; Rahim AK
    J Prim Care Community Health; 2024; 15():21501319231223437. PubMed ID: 38185870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes.
    Tokita J; Vega A; Sinfield C; Naik N; Rathi S; Martin S; Wang S; Amoruso L; Zabetian A; Coca SG; Nadkarni GN; Fleming F; Donovan MJ; Fields R
    J Prim Care Community Health; 2022; 13():21501319221138196. PubMed ID: 36404761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
    Lam D; Nadkarni GN; Mosoyan G; Neal B; Mahaffey KW; Rosenthal N; Hansen MK; Heerspink HJL; Fleming F; Coca SG
    Am J Nephrol; 2022; 53(1):21-31. PubMed ID: 35016188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A kidney diagnostic's impact on physician decision-making in diabetic kidney disease.
    Datar M; Ramakrishnan S; Chong J; Montgomery E; Goss TF; Coca SG; Vassalotti JA
    Am J Manag Care; 2022 Dec; 28(12):654-661. PubMed ID: 36525658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.
    Chan L; Nadkarni GN; Fleming F; McCullough JR; Connolly P; Mosoyan G; El Salem F; Kattan MW; Vassalotti JA; Murphy B; Donovan MJ; Coca SG; Damrauer SM
    Diabetologia; 2021 Jul; 64(7):1504-1515. PubMed ID: 33797560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
    Nadkarni GN; Stapleton S; Takale D; Edwards K; Moran K; Mosoyan G; Hansen MK; Donovan MJ; Heerspink HJL; Fleming F; Coca SG
    Diabetes Obes Metab; 2023 Dec; 25(12):3779-3787. PubMed ID: 37722962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Payer budget impact of an artificial intelligence
    Datar M; Burchenal W; Donovan MJ; Coca SG; Wang E; Goss TF
    J Med Econ; 2021; 24(1):972-982. PubMed ID: 34304681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes.
    Chauhan K; Nadkarni GN; Fleming F; McCullough J; He CJ; Quackenbush J; Murphy B; Donovan MJ; Coca SG; Bonventre JV
    Kidney360; 2020 Aug; 1(8):731-739. PubMed ID: 35372952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation Between Serum 25-Hydroxyvitamin D Levels in Albuminuria Progression of Diabetic Kidney Disease and Underlying Mechanisms By Bioinformatics Analysis.
    Huang B; Wen W; Ye S
    Front Endocrinol (Lausanne); 2022; 13():880930. PubMed ID: 35634488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.
    Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sanchez FJ; Gómez Huelgas R; Mateos Polo L; Varela Aguilar JM; Suárez Tembra JM; Arévalo-Lorido JC;
    Int J Clin Pract; 2020 Oct; 74(10):e13586. PubMed ID: 32533906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrochemical Skin Conductance in Diabetic Kidney Disease.
    Freedman BI; Smith SC; Bagwell BM; Xu J; Bowden DW; Divers J
    Am J Nephrol; 2015; 41(6):438-47. PubMed ID: 26228248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
    Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
    Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral structural changes in diabetic kidney disease: African American-Diabetes Heart Study MIND.
    Sink KM; Divers J; Whitlow CT; Palmer ND; Smith SC; Xu J; Hugenschmidt CE; Wagner BC; Williamson JD; Bowden DW; Maldjian JA; Freedman BI
    Diabetes Care; 2015 Feb; 38(2):206-12. PubMed ID: 25205141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
    Schechter M; Melzer Cohen C; Fishkin A; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Chodick G; Clark A; Abrahamsen TJ; Lawson J; Karasik A; Mosenzon O
    Cardiovasc Diabetol; 2023 May; 22(1):126. PubMed ID: 37244998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic Kidney Disease Without Albuminuria: A New Entity in Diabetic Nephropathy.
    Ahmadi N; Amouzegar A
    Iran J Kidney Dis; 2024 Jan; 1(1):1-8. PubMed ID: 38308545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel assessment of albuminuria and plasma sTNFR1 in people with type 2 diabetes and advanced chronic kidney disease provides accurate prognostication of the risks of renal decline and death.
    Martin WP; Tuohy C; Doody A; Jackson S; Canavan RJ; Slattery D; Twomey PJ; McKenna MJ; le Roux CW; Docherty NG
    Sci Rep; 2020 Sep; 10(1):14852. PubMed ID: 32908199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk and renal injury profile in subjects with type 2 diabetes and non-albuminuric diabetic kidney disease.
    Di Marco M; Scilletta S; Miano N; Marrano N; Natalicchio A; Giorgino F; Di Mauro S; Filippello A; Scamporrino A; Tribulato P; Bosco G; Di Giacomo Barbagallo F; Scicali R; Milluzzo A; Ballirò T; Frittitta L; Castellino P; Purrello F; Piro S; Di Pino A
    Cardiovasc Diabetol; 2023 Dec; 22(1):344. PubMed ID: 38093293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.